Alluvi, previously BI 4744, offers a promising breakthrough in weight control treatment. This dual stimulator targeting both GLP-1 and GIP targets demonstrates remarkable results in clinical assessments, potentially https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/